Ceretype Neuromedicine Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ceretype Neuromedicine's estimated annual revenue is currently $697.5k per year.(i)
  • Ceretype Neuromedicine's estimated revenue per employee is $77,500

Employee Data

  • Ceretype Neuromedicine has 9 Employees.(i)
  • Ceretype Neuromedicine grew their employee count by 50% last year.

Ceretype Neuromedicine's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Ceretype Neuromedicine?

Ceretype Neuromedicine, Inc. is a development-stage company applying its revolutionary, AI-based fMRI brain biomarker technologies to improve drug discovery and patient care. Through its unique ability to sub-type and classify the human brain on a neurobiological level, the Company offers novel, precise, biologically-based diagnostic and therapeutic strategies to address psychiatric illness and central nervous system disorders, fundamentally transforming the field of mental health. Based in Cambridge Massachusetts, Ceretype is founded on seminal scientific discoveries made in the laboratory of Drs. Emily Stern, David Silbersweig and Hong Pan at Brigham and Women’s Hospital/Harvard Medical School (BWH/HMS). Prior to its launch, Ceretype’s founders spent the previous decade at BWH/HMS discovering, refining and patenting its key underlying technologies. The Company launched its initial operations in February 2020 upon its CEO’s separation from BWH/HMS.

keywords:N/A

N/A

Total Funding

9

Number of Employees

$697.5k

Revenue (est)

50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M9N/AN/A
#2
$0.7M9N/AN/A
#3
$0.7M9-10%N/A
#4
$0.7M9-71%$138.8M
#5
$0.7M9-25%N/A